Related Experiment Video
Updated: Jul 25, 2025
08:26
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
2.0K
Molecular Testing in Ovarian Tumours: Challenges from the Pathologist's Perspective
1Department of Cellular Pathology, University College London NHS Trust, 60 Whitfield Street, London W1T 4E, UK.
Diagnostics (Basel, Switzerland)
|June 28, 2023
Summary
Routine homologous recombination deficiency (HRD) testing for ovarian tumors increases pathologist workload. Clear communication pathways and improved tissue handling are crucial for optimizing molecular diagnostics and patient care.
Area of Science:
- Oncology
- Pathology
- Genomics
Background:
- Molecular testing, particularly homologous recombination deficiency (HRD) testing, is increasingly standard for high-grade ovarian epithelial tumors.
- This expansion significantly impacts pathologists regarding workload, sample adequacy, and report interpretation.
Purpose of the Study:
- To discuss the implications of increased molecular testing for clinical histopathologists.
- To highlight the need for optimized communication and processes in molecular diagnostics for ovarian tumors.
Main Methods:
- Review of current practices and challenges in molecular testing for ovarian tumors.
- Discussion of national (Genomic Laboratory Hubs) and local strategies for improving diagnostic quality.
Main Results:
- Increased molecular testing necessitates enhanced pathologist support and training.
- Effective communication between clinicians, pathology staff, and scientists is vital.
Conclusions:
- Establishing clear communication pathways at local and national levels is essential.
- Improving tissue quality and streamlining testing request processes can optimize molecular pathology services for ovarian cancer patients.
